Evaluation of Disparities in Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patient Treatment Patterns in a Large US Health System

被引：0
|
作者：
Moore, Kristin J. [1 ]
Engel-Nitz, Nicole M. [1 ]
McMahon, Peter [2 ]
Beal, Jason [2 ]
Jhaveri, Teraneh Z. [2 ]
Williamson, Mellissa [2 ]
Andrade, Katherine [1 ]
Landis, Christina [1 ]
Sadek, Islam [2 ]
Hogea, Cosmina [2 ]
机构：
[1] Optum, Eden Prairie, MN USA
[2] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182031
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [42] Impact of Treatment on Overall Survival (OS) in Higher-Risk Myelodysplastic Syndromes (MDS): A Report from the Erasme Study
    Arnan, Montserrat
    Coll, Rosa
    Tormo, Mar
    Maria Bastida, Jose
    Calbacho, Maria
    Bernal, Teresa
    Ramos, Fernando
    Somolinos, Nieves
    Pedro, Carmen
    Albors, Manuel
    Marchante, Inmaculada
    Brunet, Salut
    Rafel, Montse
    Valcarcel, David
    BLOOD, 2015, 126 (23)
  • [43] Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S56 - S59
  • [44] Azacitidine and Venetoclax Combination for Upfront Treatment of Higher-Risk Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Chan, Onyee
    Padron, Eric
    Sweet, Kendra
    Kuykendall, Andrew
    Lancet, Jeffrey
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S341 - S341
  • [45] ACCURACY OF PHYSICIAN ASSESSMENT OF TREATMENT PREFERENCES AND HEALTH STATUS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES
    Caocci, G.
    Voso, M. T.
    Angelucci, E.
    Stauder, R.
    Cottone, F.
    Abel, G.
    Nguyen, K. T. T.
    Platzbecker, U.
    Beyne-Rauzy, O.
    Gaidano, G.
    Invernizzi, R.
    Molica, S.
    Criscuolo, M.
    Breccia, M.
    Luebbert, M.
    Sanpaolo, G.
    Buccisano, F.
    Ricco, A.
    Palumbo, G.
    Niscola, P.
    Zhang, H.
    Fenu, S.
    La Nasa, G.
    Mandelli, F.
    Efficace, F.
    HAEMATOLOGICA, 2015, 100 : 23 - 23
  • [46] Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
    Garcia-Manero, Guillermo
    Jonasova, Anna
    Luger, Selina M.
    Al-Kali, Aref
    Valcarcel, David
    Warlick, Erica D.
    Jedrzejczak, Wieslaw W.
    Diez-Campelo, Maria
    Zbyszewski, Patrick S.
    Cavanaugh, Christopher
    Woodman, Richard C.
    Fruchtman, Steven M.
    Takahashi, Koichi
    BLOOD, 2019, 134
  • [47] The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid Leukemia
    Zeidan, Amer
    Esteve, Jordi
    Kim, Hee-Je
    Miyazaki, Yasushi
    Platzbecker, Uwe
    Schuh, Andre
    Westermann, Joerg
    Malek, Kamel
    Scott, Jeffrey
    Niolat, Julie
    Peyrard, Severine
    Kiertsman, Flavia
    Stegert, Mario
    Fenaux, Pierre
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S188 - S188
  • [48] Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA)
    Komrokji, Rami S.
    Donoso, Leyla Hernandez
    Hodzic, Sejla
    Owusu, Henry F.
    Nolan, Kevin
    Nourry, Claire
    Diez-Campelo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)
    Bewersdorf, Jan Philipp
    Hasle, Vanessa
    Shallis, Rory Michael
    Thompson, Ethan G.
    de Menezes, Daniel Lopes
    Rose, Shelonitda
    Boss, Isaac W.
    Halene, Stephanie
    Haferlach, Torsten
    Fox, Brian
    Zeidan, Amer M.
    BLOOD, 2022, 140 : 8910 - 8911
  • [50] Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes
    Levy, A. R.
    Zou, D.
    Risebrough, N.
    Buckstein, R.
    Kim, T.
    Brereton, N.
    CURRENT ONCOLOGY, 2014, 21 (01) : E29 - E40
12345